Dasatinib Accord

Country: European Union

Language: Bulgarian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

дазатиниб

Available from:

Accord Healthcare S.L.U.

ATC code:

L01EA02

INN (International Name):

dasatinib (anhydrous)

Therapeutic group:

Антинеопластични средства

Therapeutic area:

Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Therapeutic indications:

Dasatinib Accord is indicated for the treatment of adult patients with:• Ph+ acute lymphoblastic leukaemia (ALL) with resistance or intolerance to prior therapy. Dasatinib Accord is indicated for the treatment of paediatric patients with:• newly diagnosed Ph+ ALL in combination with chemotherapy.

Product summary:

Revision: 1

Authorization status:

Отменено

Authorization date:

2022-03-24

Patient Information leaflet

                                52
Б. ЛИСТОВКА
Лекарствен продукт с невалидно
разрешение за употреба
53
ЛИСТОВКА: ИНФОРМАЦИЯ ЗА ПОТРЕБИТЕЛЯ
ДАЗАТИНИБ
ACCORD 20 MG ФИЛМИРАНИ ТАБЛЕТКИ
ДАЗАТИНИБ ACCORD 50 MG ФИЛМИРАНИ ТАБЛЕТКИ
ДАЗАТИНИБ ACCORD 70 MG ФИЛМИРАНИ ТАБЛЕТКИ
ДАЗАТИНИБ ACCORD 80 MG ФИЛМИРАНИ ТАБЛЕТКИ
ДАЗАТИНИБ ACCORD 100 MG ФИЛМИРАНИ ТАБЛЕТКИ
ДАЗАТИНИБ ACCORD 140 MG ФИЛМИРАНИ ТАБЛЕТКИ
дазатиниб (dasatinib)
ПРОЧЕТЕТЕ ВНИМАТЕЛНО ЦЯЛАТА ЛИСТОВКА
ПРЕДИ ДА ЗАПОЧНЕТЕ ДА ПРИЕМАТЕ ТОВА
ЛЕКАРСТВО,
ТЪЙ КАТО ТЯ СЪДЪРЖА ВАЖНА ЗА ВАС
ИНФОРМАЦИЯ.
-
Запазете тази листовка. Може да се
наложи да я прочетете отново.
-
Ако имате някакви допълнителни
въпроси, попитайте Вашия лекар или
фармацевт.
-
Това лекарство е предписано лично на
Вас. Не го преотстъпвайте на други
хора. То може
да им навреди, независимо че
признаците на тяхното заболяване са
същите като Вашите.
-
Ако получите някакви нежелани
лекарствени реакции, уведомете Вашия
лекар или
фармацевт. Това включва и всички
възможни нежелани реакции, неописани
в тази
листовка. Вижте точка 4.
КАКВО СЪДЪРЖА ТАЗИ ЛИСТОВКА:
1.
Какво представлява Дазатиниб Accord и за
какво се използва
2.
Какво трябва да знаете преди да
приемете Дазатиниб Accord
3.
Ка
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
ПРИЛОЖЕНИЕ I
КРАТКА ХАРАКТЕРИСТИКА НА ПРОДУКТА
Лекарствен продукт с невалидно
разрешение за употреба
2
1.
ИМЕ НА ЛЕКАРСТВЕНИЯ ПРОДУКТ
Дазатиниб Accord 20 mg филмирани таблетки
Дазатиниб Accord 50 mg филмирани таблетки
Дазатиниб Accord 70 mg филмирани таблетки
Дазатиниб Accord 80 mg филмирани таблетки
Дазатиниб Accord 100 mg филмирани таблетки
Дазатиниб Accord 140 mg филмирани таблетки
2.
КАЧЕСТВЕН И КОЛИЧЕСТВЕН СЪСТАВ
Дазатиниб Accord
20 mg филмирани таблетки
Всяка филмирана таблетка съдържа 20 mg
дазатиниб (dasatinib).
_ _
_Помощнo веществo с известно действие _
Всяка филмирана таблетка съдържа 27 mg
лактоза (като монохидрат).
Дазатиниб Accord
50 mg филмирани таблетки
Всяка филмирана таблетка съдържа 50 mg
дазатиниб (dasatinib).
_ _
_Помощнo веществo с известно действие _
Всяка филмирана таблетка съдържа 67,5 mg
лактоза (като монохидрат).
Дазатиниб Accord
70 mg филмирани таблетки
Всяка филмирана таблетка съдържа 70 mg
дазатиниб (dasatinib).
_ _
_Помощнo веществo с известно действие _
Всяка филмирана таблетка съдържа 94,5 mg
лактоза (като монохидрат).
Дазатиниб Accord
80 mg филмирани таблетки
Всяка филмирана таблетка съдържа 80 mg
дазатиниб (dasatinib).
_ _
_Помощнo веществo с известно действие _
Всяка
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Spanish 30-03-2023
Public Assessment Report Public Assessment Report Spanish 30-03-2023
Patient Information leaflet Patient Information leaflet Czech 30-03-2023
Public Assessment Report Public Assessment Report Czech 30-03-2023
Patient Information leaflet Patient Information leaflet Danish 30-03-2023
Public Assessment Report Public Assessment Report Danish 30-03-2023
Patient Information leaflet Patient Information leaflet German 30-03-2023
Public Assessment Report Public Assessment Report German 30-03-2023
Patient Information leaflet Patient Information leaflet Estonian 30-03-2023
Public Assessment Report Public Assessment Report Estonian 30-03-2023
Patient Information leaflet Patient Information leaflet Greek 30-03-2023
Public Assessment Report Public Assessment Report Greek 30-03-2023
Patient Information leaflet Patient Information leaflet English 30-03-2023
Public Assessment Report Public Assessment Report English 30-03-2023
Patient Information leaflet Patient Information leaflet French 30-03-2023
Public Assessment Report Public Assessment Report French 30-03-2023
Patient Information leaflet Patient Information leaflet Italian 30-03-2023
Public Assessment Report Public Assessment Report Italian 30-03-2023
Patient Information leaflet Patient Information leaflet Latvian 30-03-2023
Public Assessment Report Public Assessment Report Latvian 30-03-2023
Patient Information leaflet Patient Information leaflet Lithuanian 30-03-2023
Summary of Product characteristics Summary of Product characteristics Lithuanian 30-03-2023
Public Assessment Report Public Assessment Report Lithuanian 30-03-2023
Patient Information leaflet Patient Information leaflet Hungarian 30-03-2023
Summary of Product characteristics Summary of Product characteristics Hungarian 30-03-2023
Public Assessment Report Public Assessment Report Hungarian 30-03-2023
Patient Information leaflet Patient Information leaflet Maltese 30-03-2023
Public Assessment Report Public Assessment Report Maltese 30-03-2023
Patient Information leaflet Patient Information leaflet Dutch 30-03-2023
Public Assessment Report Public Assessment Report Dutch 30-03-2023
Patient Information leaflet Patient Information leaflet Polish 30-03-2023
Public Assessment Report Public Assessment Report Polish 30-03-2023
Patient Information leaflet Patient Information leaflet Portuguese 30-03-2023
Summary of Product characteristics Summary of Product characteristics Portuguese 30-03-2023
Public Assessment Report Public Assessment Report Portuguese 30-03-2023
Patient Information leaflet Patient Information leaflet Romanian 30-03-2023
Public Assessment Report Public Assessment Report Romanian 30-03-2023
Patient Information leaflet Patient Information leaflet Slovak 30-03-2023
Public Assessment Report Public Assessment Report Slovak 30-03-2023
Patient Information leaflet Patient Information leaflet Slovenian 30-03-2023
Summary of Product characteristics Summary of Product characteristics Slovenian 30-03-2023
Public Assessment Report Public Assessment Report Slovenian 30-03-2023
Patient Information leaflet Patient Information leaflet Finnish 30-03-2023
Public Assessment Report Public Assessment Report Finnish 30-03-2023
Patient Information leaflet Patient Information leaflet Swedish 30-03-2023
Public Assessment Report Public Assessment Report Swedish 30-03-2023
Patient Information leaflet Patient Information leaflet Norwegian 30-03-2023
Summary of Product characteristics Summary of Product characteristics Norwegian 30-03-2023
Patient Information leaflet Patient Information leaflet Icelandic 30-03-2023
Summary of Product characteristics Summary of Product characteristics Icelandic 30-03-2023
Patient Information leaflet Patient Information leaflet Croatian 30-03-2023
Public Assessment Report Public Assessment Report Croatian 30-03-2023

Search alerts related to this product